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In this Commentary, McKee et al. highlight the properties of extrinsic vaccine adjuvants that must be
considered to achieve the most protective immune response, as occurs naturally with many intrinsic
pathogen-derived adjuvants.The idea that somematerials could im-
prove immune responses was recog-
nized many years ago with the work
of William Coley, who used bacterial
products to treat cancer patients, and
Ramon and Glenny, who used unex-
pected reagents such as tapioca and
aluminum hydroxide to improve the re-
sponses of horses or guinea pigs to
diphtheria and tetanus toxoids (Coley,
1893;Ramon,1925;Glennyetal., 1926).
Adjuvants can act in several nonmu-
tually exclusive ways to augment the
adaptive immune responseand togen-
erate effective immunologicalmemory.
Many of their effects seem to be on
antigen-presenting cells such as den-
dritic cells (DCs). Thereby adjuvants
can affect the migration, maturation,
antigen presentation, and expression
of costimulatory molecules by DCs,
and these events in turn improve the
responses to antigen of T and B cells.
Adjuvants, apparently via DCs, can
also affect the nature of CD4 T helper
(Th), CD8 T cell, and B cell responses,
with some adjuvants promoting Th1-
related responsesandotherspreferen-
tially inducing Th2-biased effects. Fur-
thermore, some adjuvants enhance
crosspresentation by DCs of MHC I-
restricted antigens to CD8+ T cells.
Adjuvants may also act directly on T
or B cells, improving their proliferation
and/or conversion into memory cells
that are essential for the success of
vaccines.
Many vaccines were developed in
the 19th and 20th centuries against dis-
eases such as measles, smallpox, and
yellow fever, diseases that are nowcontrolled to a large extent in devel-
oped countries by vaccine-induced
antibody. However, despite the in-
crease in our knowledge of the im-
mune system and micro-organisms,
we still lack effective vaccines for
many diseases. This may be because
the invader is too clever for us; an
effective vaccine may simply not be
possible. On the other hand, the vac-
cine design may not have been opti-
mal. For example, some infections
may be better dealt with by a particular
antibody isotype, and the vaccine used
may not have induced the correct type
of antibody. Also, antibodies are not
protective against some intracellular
pathogens, and T cell responses may
be more effective, so the recent
emphasis on T cell-stimulating rather
than the antibody-inducing vaccines
that have been used in the past may
be really helpful in such cases. Be-
cause the choice of adjuvant can affect
the isotype of antibody and the nature
of the T cells produced, new strategies
with these points in mind require care-
ful choice of adjuvant.
Different Infections Are Best
Dealt With by Different Types
of Immunity
The vast majority of viruses are con-
trolled well by the current vaccines
that act by inducing antibodies. Even
for the successful vaccines of this
type there may, however, be room for
improvement. For example, the sub-
unit influenza vaccine given in the
USA currently includes no adjuvant,
according to the manufacturers. OneImmunity 27,would predict that influenza infection
wouldbestbepreventedwithavaccine
containing an adjuvant that induces
IgA and IgG2a responses, and efforts
to create such a vaccine are underway.
In this case the adjuvantmay act on the
B cells themselves, but, more likely,
would act on DCs, which, in turn, mod-
ulate the type of CD4+ helper T cell
produced.
For some intracellular pathogens,
such as M. tuberculosis and L. major
(Foulds et al., 2006; Kaufmann, 2006),
CD4+ T cells that have differentiated
into Th1 cells are most protective. Th1
cells mediate direct effects on such
pathogens via production of interferon
gamma (IFN-g) and tumor necrosis fac-
toralpha (TNF-a) andalsobypromoting
the effector functions and survival of
CD8+ T cells. Conversely, Th2 CD4+
cells, secreting interleukin (IL)-4, IL-5,
and IL-13, protect against helminth in-
fections (Stetson et al., 2004), and
Th17 cells, secreting primarily IL-17,
may participate in promoting innate re-
sponses against extracellular bacteria
(Stockinger and Veldhoen, 2007).
What Adjuvants Are Currently
Available for Use in Vaccines
and How Do They Function?
Many of the vaccines currently used in
man contain adjuvants that are intrin-
sic to the immunogen. For example,
vaccines that contain attenuated live
or heat-killed viruses or bacteria in-
clude components that can engage
Toll-like receptors (TLRs) (Tables 1
and 2). These components therefore
act as natural adjuvants because TLRNovember 2007 ª2007 Elsevier Inc. 687
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CommentaryTable 1. Some Products of Invading Organisms that Engage Innate
Receptors
Material Source Innate Receptor
Peptidyl glycans bacteria TLR1,2,6
Lipoproteins bacteria TLR1,2,6
GPI trypanosomes/plasmodia TLR1,2,6
dsRNA viruses TLR3
Lipid A bacteria TLR4
Flagellin bacteria TLR5
ssRNA viruses TLR7,8
Unmethylated CpG bacteria/viruses TLR9
Hemozoin pigment malaria TLR9
Profilin protozoa TLR11 (mouse only)
Peptidoglycan bacteria Nod1
Muramyl dipeptide bacteria Nod2
Anthrax lethal toxin B. anthracis NALP1b
Uric acid crystals endogenous NALP3, Cryopyrin
Calcium pyrophosphate endogenous NALP3, Cryopyrin
Lipopolysaccharide bacteria NALP3, Cryopyrin
dsRNA viruses NALP3, Cryopyrin
Flagellin S. typhimurium Ipaf
Flagellin L. pneumophila NALP5, Ipaf
dsDNA viruses RIG-I, MAVS
dsRNA viruses RIG-I, MAVS
Viral glycoproteins HIV DC-SIGN
Mannose
oligosaccharides
protozoa/fungi/bacteria/
viruses
mannose binding lectin
Oligosaccharides bacteria/viruses surfactant A, D
Zymosan yeast Complement, Dectin-1
Abbreviations: GPI, glycophosphatidylinositol; ssRNA, single stranded RNA; dsDNA,
double strandedDNA; TLR, toll-like receptor; Nod, nucleotide-binding oligomerization
domain protein 1; NALP, NACHT- and LRR-containing protein; Ipaf, Nod-like receptor
family member containing ICE protease activating factor; RIG-1, retinoic acid induc-
ible protein; MAVS, mitochondrial antiviral signaling protein; DC-SIGN, dendritic
cell-specific ICAM3 grabbing nonintegrin.signaling has many of the effects on
DC antigen presentation that one
would wish for an adjuvant: improve-
ment in antigen presentation and in-
creases in costimulatory molecules
and cytokine production, leading
usually to improved Th1-related re-
sponses. Such responses are well
suited to defend against the organisms
involved, probably because TLRs have
been designed through evolution to
respond in exactly the appropriate
way to these infections and their atten-
dant, intrinsic adjuvants.688 Immunity 27, November 2007 ª2007Ironically, because TLR ligands usu-
ally work very well and induce exces-
sive and toxic inflammation, they are
not approved additives to subunit
vaccines. For example, the hepatitis B
vaccine contains protein subunits but
not intrinsic TLR ligands that are com-
ponents of the whole virus. Therefore,
there has been a flurry of research into
separating the unwanted toxic side
effects of TLR ligands from their ability
to promote cellular immunity. For ex-
ample, lipopolysaccharide (LPS) is
a powerful adjuvant but is too toxic toElsevier Inc.be safely used in human vaccines. Hy-
drolysis of the bioactive lipid A in LPS
results in amolecule calledmonophos-
phoryl lipid A (MPL). This adjuvant has
reduced toxicity compared with lipid
A but still engages TLR4 and Toll-
IL-1 receptor (TIR) domain-containing
adaptor inducing interferon b adaptor
protein that contains a TIR domain
(TRIF)-mediated signaling pathways
to enhance cellular immunity (Mata-
Haro et al., 2007).
More problematic are the vaccines
that depend on adjuvants that are not
characteristic of the targetedorganism.
Here evolutionary selection hasnot had
a chance to play its part, and the artifi-
cially included adjuvantmay not induce
the appropriate response. Of the artifi-
cially added materials, by far the most
widely used are the particulate adju-
vants based on aluminum salt precipi-
tates, called herein alum (Table 2).
Alum activates innate responses
in vivo and promotes a Th2-biased
response and elevated titers of the
Th2-dependent antibody isotypes IgG1
and IgE.
Despite its long use, we still do not
know exactly how alum mediates its
adjuvant effects. One hypothesis is
that alum, because it adsorbs antigens,
servesasa depot, releasing theantigen
slowly into the body, thereby allowing
antigen-specific lymphocytes to be
exposed toantigen for a longer time.Al-
though alum certainly extends the half-
life of antigen in vivo,whether the depot
theory accounts for its adjuvanticity has
been challenged in several studies. For
example, removal of the alum depot at
the site of injection 1 week after immu-
nization had no effect on the antibody
response that developed against the
coinjected antigen (Holt, 1950), and in
some cases antigens are rapidly re-
leased from the supposed alum depot.
Moreover, stable adsorption of an anti-
gen to alum is not necessary for alum’s
ability topotentiateantibody responses
(Iyer et al., 2003).
Alum is certainly recognized by the
body, as shown by the fact that it
causes rapid influxes of neutrophils
and eosinophils at its site of injection
(Walls, 1977), induces the appearance
of Gr1+, IL-4-secreting cells in the
spleen (Jordan et al., 2004), and mark-
edly biases responses toward a Th2
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CommentaryTable 2. Adjuvants Routinely Used in Vaccines
Vaccine (Past and Present) Added Adjuvant
Diphtheria, Pertussis, Tetanus Alum
Hepatitis A Alum
Hepatitis B Alum
Haemophilus influenzae
polysaccharides
Alum
Meningococcal polysaccharides Alum
Pneumococcal polysaccharides Alum
Vaccine (Past and Present) Intrinsic Adjuvant
Rabies ssRNA, dsRNA, CpG
Polio ssRNA, dsRNA, CpG
Measles, Mumps, Rubella ssRNA, dsRNA, CpG
Varicella ssRNA, dsRNA, CpG
Vaccinia ssRNA, dsRNA, CpG
Yellow fever virus ssRNA, dsRNA, CpG
Typhoid Peptidoglycan, LPS, CpG, Flagellin
Cholera Peptidoglycan, LPS, CpG, Flagellin
B. Calmette Guerin (for TB and leprosy) Peptidoglycan, LPS, CpG, Flagellin
Anthrax Peptidoglycan, LPS, CpG, Flagellin
Vaccines in Development Combination Adjuvant
P. falciparum Circumzoite protein MPL (TLR4), QS21, MF59 (AS02) + HBV
virion particles
Papilloma capsid Alum + MPL (AS04) + virion particles
Abbreviations: ssRNA, single-stranded RNA; dsRNA, double-stranded RNA; TB,
tuberculosis; LPS, lipopolysaccharide; P. falciparum, Plasmodium falciparum; MPL,
monophophoryl lipid; TLR, toll-like receptor; HBV, hepatitis B virus.phenotype. Alum is not recognized by
TLRs. In fact, TLR agonists override
the Th2-biasing effects of alum. How-
ever, other innate receptors may be
involved: for example, NALP3, which
activates the inflammasome and
caspase-1 in response to other kinds
of crystals such as those of uric acid
(Martinon et al., 2006). Clues to recep-
tors may also come from materials
that, like alum, induce eosinophilic ex-
udates and Th2-biased immune re-
sponses. These materials include hel-
minth eggs, chitin polymers, and
many other types of particles (Reese
et al., 2007; Sabin et al., 1996).
Alum fixes complement, and a re-
cent paper showed that complement
component 3 (C3)-deficient mice
make poorer immune responses than
do wild-type animals to antigen plus
alum (Yalcindag et al., 2006). However,
C3-deficient animals make poor im-mune responses to antigens regard-
less of the adjuvant (Pepys, 1974).
Thus, the need for complement is not
particular to alum. Foreign body reac-
tions are driven by fibrinogen deposi-
tion and breakdown on implants, so
the clotting cascade may be involved
in alum recognition, an idea that needs
further investigation in vivo.
An obvious thought is that alum’s
ability to induce T cells with a Th2 phe-
notype depends on its effects on DCs.
Like other Th2-inducing DCs, DCs ex-
posed directly to alum do not fully up-
regulate costimulatory molecules and
do not produce Th1-driving cytokines,
the canonical changes to DC induced
by TLR signals (Sokolovska et al.,
2007). Rather, alum enhances the se-
cretion of IL-1b and IL-18 by DCs by
activating caspase-1 in a myeloid dif-
ferentiation factor 88 (MyD88)-inde-
pendent manner (Li et al., 2007). How-Immunity 27,ever, IL-1r1-deficient mice sensitized
with alum and ovalbumin have
asthma-related Th2 responses and
pathology similar to those of wild-
type mice (Schmitz et al., 2003) and
IL-18 plays only a partial role in T cell
responses to alum in vivo (Pollock
et al., 2003). Likewise, T cells gener-
ated with alum-exposed DC in vitro
have an unbiased cytokine phenotype
(Sokolovska et al., 2007). Thus, alum
may not bias T cell responses via DCs.
The Th2-biasing properties of alum
may instead be based on its effects
on other cells, and in fact, the bias
may not be due to induction of Th2 re-
sponse but rather suppression of Th1
response. Thus, administration of anti-
gen plus alum in the absence of IL-4 al-
lows good T cell responses, which are
now unbiased, with T cells secreting
both IFN-g and IL-4 and both IgG1
and IgG2a isotypes (Brewer et al.,
1996). The source of the relevant IL-4
remains to be determined, because
multiple cell types can produce this cy-
tokine.
Emulsion adjuvants are also often
used in experimental animals and, in-
creasingly, in man. Such adjuvants
are classified as being either water-
in-oil or oil-in-water formulations, and
some contain other immunostimula-
tory substances. The original water-
in-oil adjuvants developed by Freund
induce adverse toxicity and are rela-
tively unstable, qualities that make
them unacceptable for use in human
vaccines. The oil-in-water adjuvant
MF59 is licensed in Europe and pro-
motes protective antibody responses
that are Th2 in nature (Ott et al.,
1995). This emulsion-based vaccine
forms smaller droplets than Freund
adjuvants, is more stable over time,
and promotes fewer adverse side ef-
fects than do water-in-oil adjuvants. It
is not known how MF59 and related
adjuvants function. Because they are
particles, their modus operandi may
be related to that of alum.
Other effective adjuvants include
QuilA, a soluble extract from the bark
of the Quillaja saponaria tree, which
contains multiple saponins. Although
QuilA is highly effective, it is also too
toxic for use in humans, causing se-
vere local reactions, granulomas, and
hemolysis. QS21 (Quillaja saponariaNovember 2007 ª2007 Elsevier Inc. 689
Immunity
Commentaryfraction 21) is a less toxic fraction puri-
fied from QuilA. Although it promotes
Th1 responses against antigens with
which it is coinjected (Wong et al.,
1999), its effects on Th1 responses
and on CD8+ T cell responses are
more successful when this adjuvant
is combined with others such as the
AS02 adjuvant formulation that con-
tains a combination of the oil-in-water
emulsion MF59, QS21, and mono-
phosphoryl lipid (see below).
Intrinsic microbial ligands for TLRs
are likely to be present in several hu-
man vaccines (Tables 1 and 2). Several
combinations of the adjuvants dis-
cussed above are promising for im-
proving vaccine efficacy against
pathogens that so far have eluded vac-
cinologists. Two such adjuvants are
AS04 and AS02, which have been
tested in multiple clinical trials. AS04
is a combination of alum and the LPS
derivative MPL (see above and Table
2). AS02 is a combination adjuvant of
the oil-in-water emulsion MF59 with
MPL and the saponin fraction QS21
(see above and Table 2). It is clear
that development of a successful
new generation of vaccines will require
careful consideration of the appropri-
ate adjuvant combination in addition
to the consideration of the correct pro-
tective epitopes. Below we discuss
two examples of how these adjuvants
are being applied to human vaccines.
There is increasing interest in vac-
cines containing more than one adju-
vant. For example, a recent promising
malarial vaccine candidate, RTS,S, is
formulated with the AS02 combination
adjuvant mentioned above. As anti-
gens, the vaccine includes a malarial
pre-erythrocytic antigen linked to hep-
atitis B surface antigen. The vaccine
forms virus-like particles, which may
also increase its immunogenicity, as
they do for the recently introduced690 Immunity 27, November 2007 ª2007papilloma virus vaccine (Pinder et al.,
2004). Immunization of children with
this vaccine resulted in 30% decrease
of infections and a 58% drop in the
number of infected individuals that de-
veloped severe disease (Alonso et al.,
2004). The children developed protec-
tive immunity against hepatitis B virus
as well.
In summary, many vaccines include,
by their very nature, adjuvants that are
naturally suited to induce an immune
response of optimal type. Other vac-
cines contain artificially added adju-
vants, and the task of the vaccinologist
now is to pick the adjuvants that in-
duce the appropriate immune re-
sponse, without damaging the host.
Our better understanding of how im-
mune responses work and how differ-
ent organisms can be attacked offers
hope for the future in this regard.
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